Myfembree denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for myfembree are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Myfembree as "Not FDA-Approved" — and Why This Denial Is Directly Challengeable

Myfembree (relugolix, estradiol, and norethindrone acetate) is an FDA-approved medication. A denial claiming it is "not FDA-approved" is factually incorrect for any use within its approved indication. This type of denial can arise from a coding error, a policy applied to the wrong drug, or a mischaracterization of an off-label use question as an approval-status question. Regardless of the cause, it is one of the most straightforwardly appealable denial types because it is based on a verifiable factual error.

## The Federal Appeal Framework

• Internal appeal (Level 1): File a written appeal within Cigna's deadline (generally 180 days from the denial). Include a copy of the FDA drug approval record as a primary exhibit. Cigna must respond within 30 days for pre-service non-urgent appeals or 72 hours for expedited urgent reviews.
• Immediate escalation option: Because this denial rests on a factual error rather than a clinical judgment, you may also contact Cigna's member services to request a rapid reconsideration — in many cases, submitting the FDA approval documentation resolves the denial without a formal appeal proceeding.
• External review (ACA §2719): If the internal appeal is denied, request independent external review — generally within 4 months of the final adverse determination. IRO reviewers have consistent authority to reverse denials premised on incorrect factual conclusions.
• ERISA §503: For employer-sponsored plans, Cigna must provide a specific written explanation for why it considers the drug unapproved — a requirement it cannot satisfy if the drug is, in fact, FDA-approved.

## Documents to Gather

1. FDA approval record: Download the current product approval record for Myfembree from FDA.gov. This is the single most important document for this appeal — it directly refutes the denial's factual premise. 2. FDA prescribing label: Print the full prescribing information. Highlight the approved indications and confirm that the prescribed use falls within them. 3. Prescriber cover letter: A brief letter from your physician confirming the diagnosis, the FDA-approved indication being invoked, and that the prescribed use is within the label. The physician should explicitly note that the denial's "not FDA-approved" basis is factually inaccurate. 4. Cigna's denial letter: Keep the original denial letter. Note the exact language used and the policy cited, which will allow you to demonstrate specifically where the analysis is wrong. 5. Diagnosis documentation: Supporting chart records confirming the underlying condition.

## Criteria-Mapping Structure

This appeal is unusually straightforward. The letter structure should be:

1. Statement of the error: "Cigna denied Myfembree on the basis that it is not FDA-approved. This is factually incorrect. Myfembree received FDA approval and is listed on the FDA drug approval database [cite the FDA URL]." 2. Applicable indication: Confirm the prescribed indication matches an FDA-approved use per the prescribing label. 3. Request: Demand reversal of the denial and authorization of the prescription.

If Cigna's denial actually intended to raise a different concern (such as off-label use or formulary status), request in writing that Cigna reissue the denial with accurate grounds so you can respond substantively. Mislabeled denials obscure your appeal rights and should be corrected before the appeal window closes.